BAFF Mutation Also Found in NHL
Some patients with non-Hodgkin lymphoma (NHL) harbor the B-cell activating factor (BAFF), new research has shown. In a study now available online in the Journal of Experimental Medicine (www.jem.org), researchers from the University of Iowa and the Mayo Clinic found that BAFF, a soluble protein needed for B-cell survival and maturation, is elevated in the blood of some NHL patients and is associated with poor prognosis.
This BAFF-R mutation generates a receptor that transmits stronger than normal signals, thus boosting B-cell function.
A news release notes that although the mutation was present in fewer than 10% of the tumors analyzed in the study, the findings provide further evidence of the importance of BAFF signaling in NHL.